Everett Harris & Co. CA decreased its stake in West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) by 1.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,757 shares of the medical instruments supplier’s stock after selling 50 shares during the quarter. Everett Harris & Co. CA’s holdings in West Pharmaceutical Services were worth $1,323,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also modified their holdings of the stock. Sunbelt Securities Inc. acquired a new position in West Pharmaceutical Services during the first quarter worth $25,000. RVW Wealth LLC purchased a new stake in shares of West Pharmaceutical Services in the third quarter valued at about $38,000. Planned Solutions Inc. purchased a new position in West Pharmaceutical Services during the fourth quarter worth about $39,000. First Horizon Advisors Inc. boosted its holdings in West Pharmaceutical Services by 37.4% in the 1st quarter. First Horizon Advisors Inc. now owns 147 shares of the medical instruments supplier’s stock valued at $51,000 after purchasing an additional 40 shares during the last quarter. Finally, International Assets Investment Management LLC purchased a new stake in shares of West Pharmaceutical Services in the 3rd quarter valued at approximately $53,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.
Insider Activity at West Pharmaceutical Services
In other news, CAO Chad Winters sold 815 shares of the stock in a transaction on Monday, March 11th. The shares were sold at an average price of $358.82, for a total value of $292,438.30. Following the completion of the sale, the chief accounting officer now owns 1,309 shares of the company’s stock, valued at $469,695.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, VP Charles Witherspoon sold 2,019 shares of West Pharmaceutical Services stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $358.62, for a total transaction of $724,053.78. Following the sale, the vice president now owns 1,979 shares in the company, valued at $709,708.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Chad Winters sold 815 shares of the firm’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $358.82, for a total transaction of $292,438.30. Following the sale, the chief accounting officer now directly owns 1,309 shares of the company’s stock, valued at $469,695.38. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 73,978 shares of company stock worth $26,653,772. Company insiders own 0.53% of the company’s stock.
Wall Street Analysts Forecast Growth
Check Out Our Latest Stock Analysis on West Pharmaceutical Services
West Pharmaceutical Services Price Performance
West Pharmaceutical Services stock traded up $1.61 during mid-day trading on Thursday, hitting $395.71. 234,704 shares of the company were exchanged, compared to its average volume of 551,421. The business’s 50 day simple moving average is $374.38 and its two-hundred day simple moving average is $363.70. West Pharmaceutical Services, Inc. has a 12-month low of $310.42 and a 12-month high of $415.73. The company has a market capitalization of $28.97 billion, a P/E ratio of 50.25, a PEG ratio of 6.63 and a beta of 1.03. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.88 and a quick ratio of 2.24.
West Pharmaceutical Services (NYSE:WST – Get Free Report) last issued its quarterly earnings results on Thursday, February 15th. The medical instruments supplier reported $1.83 EPS for the quarter, topping the consensus estimate of $1.78 by $0.05. West Pharmaceutical Services had a net margin of 20.12% and a return on equity of 21.60%. The firm had revenue of $732.00 million during the quarter, compared to analyst estimates of $740.43 million. During the same quarter in the prior year, the business posted $1.77 earnings per share. West Pharmaceutical Services’s revenue for the quarter was up 3.3% compared to the same quarter last year. Analysts forecast that West Pharmaceutical Services, Inc. will post 7.63 earnings per share for the current fiscal year.
West Pharmaceutical Services Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Wednesday, April 24th will be given a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 0.20%. The ex-dividend date of this dividend is Tuesday, April 23rd. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 10.15%.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
Recommended Stories
- Five stocks we like better than West Pharmaceutical Services
- Financial Services Stocks Investing
- 3 Value Stocks Too Small For Buffett’s Portfolio
- Basic Materials Stocks Investing
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- How to Evaluate a Stock Before Buying
- Disney Stock Catches 3 Upgrades In a Single Week
Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST – Free Report).
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.